Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.
- 96% Barchart technical buy signals
- 571.66+ Weighted Alpha
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 10 new highs and up 28.48% in the last month
- Relative Strength Index 62.95%
- Barchart computes a technical support level at 92.87
- Recently traded at 96.05 with a 50 day moving average of 82.37
Fundamental factors:
- Market Cap $1.46 billion
- P/E 1,613
- Revenue expected to increase 245.50% next year
- Earnings estimated to increase 704.80% next year
- Wall Street analysts issued 1 strong buy and 3 buy recommendations
No comments:
Post a Comment